(14:45 GMT) Kymera Therapeutics Price Target Raised to $155.00/Share From $117.00 by B. Riley Securities
Dow Jones Newswires
Kymera Therapeutics Is Maintained at Buy by B. Riley Securities
- Sources
- Dow Jones Newswires
- Markets
- Stocks
- Active symbols
- NASDAQ:KYMR
- Language
- English